Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study

OBJECTIVE: Canagliflozin, a sodium glucose cotransporter (SGLT) 2 inhibitor, is also a low-potency SGLT1 inhibitor. This study tested the hypothesis that intestinal canagliflozin levels postdose are sufficiently high to transiently inhibit intestinal SGLT1, thereby delaying intestinal glucose absorp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Polidori, David, Sha, Sue, Mudaliar, Sunder, Ciaraldi, Theodore P., Ghosh, Atalanta, Vaccaro, Nicole, Farrell, Kristin, Rothenberg, Paul, Henry, Robert R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2013
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3714520/
https://ncbi.nlm.nih.gov/pubmed/23412078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc12-2391
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados